Guide to Verzenio Treatment Indications and Eligibility

Verzenio, or abemaciclib, is a prescription medicine used for specific forms of hormone receptor positive and HER2 negative breast cancer. It may be considered for adults with high risk node positive early breast cancer alongside endocrine therapy, or for certain patients with advanced or metastatic disease.

Verzenio, also known by its generic name abemaciclib, is a prescription medicine used for certain types of hormone receptor positive and HER2 negative breast cancer. It belongs to a class of medicines called CDK4 and CDK6 inhibitors, which work by helping slow the growth and division of cancer cells. Eligibility depends on factors such as the stage of breast cancer, hormone receptor and HER2 status, lymph node involvement, recurrence risk, and previous treatments. The following information provides an overview of the treatment situations in which Verzenio may be considered.

Verzenio Treatment Indications for Early Breast Cancer

For early breast cancer, Verzenio is indicated for adults with hormone receptor positive, HER2 negative, node positive disease that has a high risk of recurrence. It is used together with endocrine therapy, such as tamoxifen or an aromatase inhibitor, as adjuvant treatment after primary treatment.

High risk is defined in the current U.S. indication using specific lymph node and tumor characteristics:

  • Four or more positive lymph nodes.
  • One to three positive lymph nodes with a tumor measuring at least 5 cm.
  • One to three positive lymph nodes with Grade 3 disease.
  • One to three positive lymph nodes when both tumor size of at least 5 cm and Grade 3 disease are present.
  • Treatment is intended for adults with HR positive and HER2 negative node positive early breast cancer.
  • Endocrine therapy is used alongside Verzenio according to the treatment plan.

These factors help healthcare professionals determine whether the potential benefit of adding Verzenio is appropriate. Treatment decisions should also consider the individual's overall health, previous treatment, and potential risks.

Verzenio Treatment Indications for Advanced Breast Cancer

Verzenio is also indicated for adults with HR positive and HER2 negative advanced or metastatic breast cancer. The treatment approach depends on previous endocrine therapy, disease progression, and whether chemotherapy has previously been used in the metastatic setting.

Common treatment situations include:

  • Verzenio with an aromatase inhibitor as initial endocrine based therapy for advanced or metastatic disease.
  • Verzenio with fulvestrant when disease has progressed following endocrine therapy.
  • Verzenio alone when disease has progressed following endocrine therapy and prior chemotherapy has been given in the metastatic setting.
  • Treatment selection may depend on menopausal status, previous medicines, disease characteristics, and overall clinical circumstances.
  • Verzenio is not established as a treatment for every breast cancer subtype.

Doctors may review pathology results, imaging, treatment history, lymph node status, tumor characteristics, and other clinical information before determining eligibility. Verzenio is a prescription medicine, so treatment should be started and monitored under appropriate medical supervision.

Verzenio has specific indications for HR positive, HER2 negative breast cancer, including certain high risk node positive early cancers and advanced or metastatic disease. Eligibility is based on established treatment criteria and individual clinical factors. Patients should discuss their diagnosis, previous treatments, possible benefits, risks, and alternatives with their healthcare professional. This article is provided for informational purposes only and does not offer sales or treatment services.